Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia.

Martin Vu Koen Degeling Ella R Thompson Piers A BlomberyDavid WestermanMaarten J IJzerman

Published in: Applied health economics and health policy (2023)

Population targeting using mutation testing for TP53 and IGHV when performed with del(17p) testing specifically in the context of frontline ibrutinib choice does not make a cost-ineffective treatment into a cost-effective treatment.

Keyphrases

chronic lymphocytic leukemia
machine learning
combination therapy
single molecule